Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Increased to $1,099.00 by Analysts at UBS Group

Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target raised by UBS Group from $1,090.00 to $1,099.00 in a report released on Wednesday, Benzinga reports. UBS Group currently has a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of a number of other reports. Royal Bank of Canada reaffirmed an […]

Related Keywords

Maryland ,United States ,Canada ,Andrewj Murphy ,Marion Mccourt ,Mezzasalma Advisors ,Royal Bank ,Regeneron Pharmaceuticals Company Profile ,Barclays ,Retirement Guys Formula ,News Ratings For Regeneron Pharmaceuticals Daily ,Regeneron Pharmaceuticals ,Marshall Financial Group ,Regeneron Pharmaceuticals Inc ,Analyst Recommendations For Regeneron Pharmaceuticals ,Regeneron Pharmaceuticals Stock Performance ,Securities Exchange Commission ,Investment Co ,Morgan Stanley ,Free Report ,Moderate Buy ,Get Free Report ,Exchange Commission ,State Retirement ,Pension System ,Financial Group ,Regeneron Pharmaceuticals Daily ,Nasdaq Regn ,Regn ,Medical ,75886f10 ,Boost Price Target ,Ubs Group Ag ,